GlassScriptPhysician profile
Meri C Arney
NPI 1760439616
$1,710.83
in general payments reported to CMS, 2019-2025
13 companies · $854 in 2025
The $854 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $327 · 2023: $108 · 2024: $181 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101 · Travel and Lodging: $40.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.49 |
| Travel and Lodging | $40.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $401.25 | 2024-2025 | Xtampza, Belbuca |
| Jazz Pharmaceuticals INC. | $215.04 | 2021-2022 | |
| Inspire Medical Systems, INC. | $179.96 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.88 | 2025 | Relistor |
| Philips North America LLC | $160.32 | 2021-2022 | |
| Abbott Laboratories | $155.15 | 2024-2025 | Proclaim |
| Lundbeck LLC | $132.01 | 2024-2025 | Vyepti |
| Alkermes, INC. | $108.24 | 2023 | Vivitrol |
| Abbvie INC. | $61.74 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $45.06 | 2024-2025 | |
| Stryker Corporation | $43.98 | 2025 | Mild Device Kit |
| Curonix LLC | $22.15 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Arbor Pharmaceuticals, INC. | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meri Arney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.